Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

NCT03120949 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2106

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Olokizumab 64 mg SC q4w
DRUG: Olokizumab 64 mg SC q2w
DRUG: Concomitant treatment

Sponsor

R-Pharm International, LLC

Collaborators

[object Object]
[object Object]